More Articles

Also noted on generics: 11 May 2012 Generics/General | Posted 11/05/2012

Out-of-pocket expenses decline in USPatients with insurance spent US$1.8 billion less on out-of-pocket expenses for medicines in 2011 compared to 2010. In 2011 patient’s out-of-pocket expenses tot...

Bayer opposes sorafenib compulsory licence in India Biosimilars/News | Posted 11/05/2012

German pharma giant Bayer told Reuters on 5 May 2012 it had challenged a decision by the Indian Government, which allows India-based generics firm Natco Pharma to sell a generic version of Bayer’s...

Also noted on pharma: 11 May 2012 Pharma News | Posted 11/05/2012

UK government considers carrying out survey on drug shortagesThe UK Department of Health (DoH) is considering a one-off survey of community pharmacies in England to assess the impact of drug short...

Abbott asks FDA to block adalimumab biosimilar Biosimilars/News | Posted 04/05/2012

Abbott Laboratories (Abbott) submitted a 30-page citizen petition to FDA on 2 April 2012 asking the agency to reject any biosimilar for its rheumatoid arthritis drug Humira (adalimumab). Abbott say...

Amgen enters biosimilars deal with PRA Pharma News | Posted 04/05/2012

Clinical Research Organisation (CRO) PRA announced on 26 April 2012 that it had entered into an agreement with US biotechnology giant Amgen as the sole provider of CRO services for ‘a series of pha...

Sandoz to gain generic dermatology specialist Fougera Generics/News | Posted 04/05/2012

Swiss pharma giant, Novartis, announced on 2 May 2012 that the company had signed a deal for Sandoz, its generics unit, to acquire speciality generics dermatology business Fougera Pharmaceuticals (...

Comparison of brand-name and biosimilar etanercept in Korea Generics/Research | Posted 04/05/2012

A study comparing pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg) in Korea reported by Gu et al has shown that the reference drug and the test biosimilar...

Bioavailability comparison of brand-name and generic acetylcysteine in China Biosimilars/Research | Posted 04/05/2012

A study comparing brand-name and generic acetylcysteine in China by Liu et al has shown that the generics test formulation was bioequivalent to the originator drug [1].